scholarly journals Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Diabetes Care ◽  
2014 ◽  
Vol 38 (3) ◽  
pp. 355-364 ◽  
Author(s):  
Lawrence A. Leiter ◽  
Kun-Ho Yoon ◽  
Pablo Arias ◽  
Gisle Langslet ◽  
John Xie ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Reduction ◽  
Phase 3 ◽  
Double Blind ◽  
Body Weight Reduction

scholarly journals Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus

2017 ◽  
Vol 26 (2) ◽  
pp. 107-113 ◽  
Author(s):  
Hyun A Cho ◽  
Young Lee Jung ◽  
Yong Hoon Lee ◽  
Yu Chang Lee ◽  
Jung Eun Lee ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Body Weight ◽  
Weight Reduction ◽  
Sglt2 Inhibitor ◽  
Body Weight Reduction

Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes

2016 ◽  
Vol 128 (8) ◽  
pp. 725-730 ◽  
Author(s):  
Guntram Schernthaner ◽  
Fernando J. Lavalle-González ◽  
Jaime A. Davidson ◽  
Holly Jodon ◽  
Ujjwala Vijapurkar ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Reduction ◽  
Body Weight Reduction

scholarly journals Postprandial Increase in Energy Expenditure Correlates with Body Weight Reduction in Patients with Type 2 Diabetes Receiving Diet Therapy

2017 ◽  
Vol 24 (4) ◽  
pp. 422-429 ◽  
Author(s):  
Daisuke Sanoyama ◽  
Mototsugu Nagao ◽  
Akira Asai ◽  
Yuko Nakamura ◽  
Kazumi Sato ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Energy Expenditure ◽  
Weight Reduction ◽  
Diet Therapy ◽  
Body Weight Reduction

scholarly journals Diastolic Cardiac Function Improvement by Liraglutide Is Mainly Body Weight Reduction Dependent but Independently Contributes to B-Type Natriuretic Peptide Reduction in Patients with Type 2 Diabetes with Preserved Ejection Fraction

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Kunimasa Yagi ◽  
Teruhiko Imamura ◽  
Hayato Tada ◽  
Daisuke Chujo ◽  
Jianhui Liu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Ejection Fraction ◽  
Cardiac Function ◽  
Natriuretic Peptide ◽  
Weight Reduction ◽  
Preserved Ejection Fraction ◽  
Body Weight Reduction ◽  
Diastolic Cardiac Function

Objectives. A single-arm prospective study was conducted among Japanese patients with type 2 diabetes having preserved ejection fraction. The aim was to investigate (1) whether liraglutide therapy could improve B-type natriuretic peptide (BNP) levels and diastolic cardiac function assessed by the E -wave to E ′ ratio ( E / E ′ ) using transthoracic echocardiography (TTE), and (2) whether E / E ′ contributed to BNP improvement independent of bodyweight reduction (UMIN000005565). Methods. Patients with type 2 diabetes and left   ventricular   ejection   fraction   LVEF ≥ 40 % without heart failure symptoms were enrolled, and daily injection with liraglutide (0.9 mg) was introduced. Cardiac functions were assessed by TTE before and after 26 weeks of liraglutide treatment. Diastolic cardiac function was defined as septal E / E ′ ≥ 13.0 . Results. Thirty-one patients were analyzed. BNP and E / E ′ improved, with BNP levels declining from 36.8 ± 30.5   pg / mL to 26.3 ± 25.9   pg / mL ( p = 0.0014 ) and E / E ′ dropping from 12.7 ± 4.7 to 11.0 ± 3.3 ( p = 0.0376 ). The LVEF showed no significant changes. E / E ′ improved only in patients with E / E ′ ≥ 13.0 . Favorable changes in E / E ′ were canceled when adjusted for body mass index (BMI). Multivariate linear regression analysis revealed that the left ventricular diastolic diameter and ∆ E / E ′ /∆BMI contributed to ∆BNP/baseline BNP ( p = 0.0075 , R 2 = 0.49264 ). Conclusions. Liraglutide had favorable effects on BNP and E / E ′ but not on LVEF. E / E ′ improvement was only seen in patients with diastolic cardiac function. Body weight reduction affected the change of E / E ′ . The BMI-adjusted E / E ′ significantly contributed to the relative change of BNP. GLP-1 analog treatment could be considered a therapeutic option against diabetic diastolic cardiac dysfunction regardless of body weight. This trial is registered with the University Hospital Medical Information Network in Japan, with clinical trial registration number: UMIN000005565.

Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes

2011 ◽  
Vol 13 (4) ◽  
pp. 374-377 ◽  
Author(s):  
M. C. Bunck ◽  
B. Eliasson ◽  
A. Cornér ◽  
R. J. Heine ◽  
R. M. Shaginian ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Body Weight ◽  
Bone Mineral ◽  
Weight Reduction ◽  
Mineral Density ◽  
Body Weight Reduction

scholarly journals Body weight reduction to avoid the excess risk of type 2 diabetes

2012 ◽  
Vol 62 (599) ◽  
pp. e411-e414 ◽  
Author(s):  
Nicholas J Wald ◽  
Jonathan P Bestwick ◽  
Joan K Morris
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Weight Reduction ◽  
Excess Risk ◽  
Body Weight Reduction
Sign in / Sign up

Export Citation Format

Share Document